Home

CARB-X has announced new 2022-2023 funding rounds! Please visit the Apply section of our website to learn more.

CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our portfolio represents the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections.

396

$million

Invested

92

innovative

Projects

12

different

Countries

12

human clinical

TRIALS

2

available

DIAGNOSTICS

2

advanced development

FUNDING

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More


2020-2021

Annual Report

CARB-X closed its fifth fiscal year on July 31, 2021 with US$361 million awarded to 92 projects since inception

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Infectious Diseases Interventions, Wellcome. Watch this video on what CARB-X is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video

 

 

Funders

ASPR
BARDA
Wellcome
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Events

Events

02.21.23

 

2023 UNIVERSAL HEALTH COVERAGE (UHC) IN AN ERA OF ANTIMICROBIAL RESISTANCE (AMR) AND PANDEMICS CONFERENCE

02.28.23

 

BIOCOM 2023

03.03.23

 

An Unfinished Life: The True Impact of Antibiotic Resistance

CARB-X News

  • 12.21.2022  |  CARB-X welcomes the G20 call to action on Antimicrobial resistance full release

  • 10.07.2022  |  CARB-X convenes at ESCMID/ASM conference to lay the groundwork for the next decade full release

  • 10.03.2022  |  CARB-X launches new funding rounds for critical global health needs full release

See All News

In The News

  • 12.19.2022  |  Superbugs Unplugged full story

  • 12.15.2022  |  How do you treat untreatable infections? Do what the microbes do. full story

  • 12.13.2022  |  Report warns that superbug threat continues to increase full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.